Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. What it means for the space, and how it…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from CNBC's "Fast Money"
See all episodes →Nvidia Shares Sink on New Allegations Against CEO Jensen Huang
CoreWeave Earnings, Nvidia Fallout and Rate Hikes Back on the Table
Nvidia Investigation Rocks Stock, Even as Broad Market Rallies
Similar episodes from other shows
More like CNBC's "Fast Money" →
What’s News in Earnings: Who Is Winning the Obesity-Drug Arms Race?
Americans Take Weight-Loss Drugs, Eat Salty Snacks
CNBC Special Report: Taking Stock 8/11/23
Stocks Rise as Oil and Yields Ease: Your Next Move 9/21/26
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.